Get the Stockscreener App
57.13
0.40%
0.23
After Hours:
57.20
0.07
+0.12%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $57.13, with a volume of 7.83M.
It is up +0.40% in the last 24 hours and up +1.20% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$56.90
Open:
$57.45
24h Volume:
7.83M
Relative Volume:
0.70
Market Cap:
$116.66B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
16.04
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-0.24%
1M Performance:
+1.20%
6M Performance:
+9.01%
1Y Performance:
+12.70%
1-Day Range:
$56.77
$57.60
1-Week Range:
$55.26
$57.60
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.13 | 116.66B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,133.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
240.87 | 579.83B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.73 | 402.35B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.05 | 294.03B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.07 | 292.07B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol-Myers Squibb Stock (US1078421011): Dividend Safety Under the Microscope - AD HOC NEWS
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. - The Motley Fool
Bristol Myers Squibb Company $BMY Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Mike Kelly sells shares in Bristol-Myers Squibb and Comcast, buys Southeast Energy Authority bonds - Investing.com Canada
Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines? - TradingView
A Congress Member Sold Up To $65K In Bristol-Myers Squibb Stock: Here's What You Need To Know - Benzinga
Bristol Myers Squibb Company $BMY Stake Lifted by Xponance LLC - MarketBeat
ICICI Prudential Asset Management Co Ltd Sells 39,000 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s AI Overhaul And Oncology Trials Shape Value Story - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis - Citeline News & Insights
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial - Reuters
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Benzinga
Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest - pharmaphorum
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test - Yahoo Finance
Loomis Sayles Strategic Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb Links Brazil Lung Cancer Access To Long Term Story - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Bristol-Myers Squibb Company (BMY) Featured in Citrini's Bullish Healthcare Basket - GuruFocus
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study - Insider Monkey
Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign - Indian Pharma Post
Inside Bristol Myers’ AI-powered procurement overhaul - CFO Dive
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.00% on Jun 8: A Full Analysis - TradingKey
Disciplined Core Equity Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Competitive approach better than restricting deals with China? - BioWorld News
Bristol Myers Squibb Tests CELMoD Research for Multiple Myeloma - Koran Manado
Mariska Hargitay Partners With Bristol Myers Squibb For Cancer Campaign - Koran Manado
Mariska Hargitay Honors Dad Mickey In Bristol Myers' Myeloma Campaign 06/08/2026 - MediaPost
Bristol Myers Squibb launches myeloma awareness campaign - Investing.com
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease - 巴士的報
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease – Company AnnouncementFT.com - Financial Times
Bristol-Myers Squibb (BMY) Investor Outlook: Analyzing a Promising 10.14% Upside and 4.40% Dividend Yield - DirectorsTalk Interviews
Israel Englander Heavily Boosts Bristol Myers Squibb Position - HarianBasis.co
Assessing Bristol Myers Squibb (BMY) Valuation After Fresh EU Opdivo Approval And New Phase 3 Oncology Data - simplywall.st
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Form 11-KAnnual report of employee stock purchase, savings and similar plans - ADVFN
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Shares Surge 3.4% -- What GF Score of 78 Tells Investors - GuruFocus
Bristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab - simplywall.st
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study - Yahoo Finance
Pharma’s ‘ugly sister’ is finally ready to offer beautiful returns - Investors' Chronicle
Bristol-Myers Squibb Outperforms Earnings Expectations Amid Market Turbulence - asatunews.co.id
Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation - Yahoo Finance
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
BMY Collaborates with Arcus Biosciences on Clinical Trial for Ca - GuruFocus
Radiation-emitting implant improves outcomes after brain cancer surgery - Reuters
Bristol-Myers Squibb stock (US1078421011): modest move as oncology data and institutional flows draw - AD HOC NEWS
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):